• Comprehensive menu in inflammatory diseases and oncology
  • Validated on principle drug and biosimilars
  • Ready to use reagents
  • Standardised protocols from sample collection to result interpretation
  • Automation ready – validated on several open platform ELISA systems

LISA-TRACKER Bevacizumab is an enzyme linked immunoassay (ELISA) for the quantitative determination of Bevacizumab (anti-VEGF) in human serum samples.

Bevacizumab is a humanised monoclonal antibody that produces angiogenesis inhibition by inhibiting the Vascular Endothelial Growth Factor (VEGF). It is indicated for the treatment of many cancers (colorectal, lung, breast, renal, ovarian, brain etc.) as it suppresses the action of the VEGF responsible for the growth of tumours.  However, during the treatment, some patients can develop antibodies against Bevacizumab.

  • Cohen M.H. et al. FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent non squamous non-small cell lung cancer, The oncologist, vol. 12, no 6, 2007, p. 713-718.
  • Connolly O. Human vascular Permeability Factor, The Journal of Biological Chemistry, 1989, vol. 264, n°33, p. 20017-20024.
  • Escudier B et al. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival.  Journal of clinical oncology, vol. 28, no 13, 2010, p. 2144-2150.
  • Ferrara N. The biology of vascular endothelial growth factor. Endocrine reviews, 1997, Vol. 18 n°1.
  • Ferrara N. Discovery and development of Bevacizumab, an anti-VEGF antibody for treating cancer. Nature reviews Drug Discovery, 2004, Vol. 3.
  • Ferrara N. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochemical and Biophysical Research Communications, 2005, 328-335.
  • Gilbert R et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma, N Engl J Med, 2014; 370:699-708.
  • Huang H.  An updated meta-analysis of fatal adverse events caused by Bevacizumab therapy in cancer patients. PLoS One, 2014, 9(3): e89960.
  • Kabbinavar F. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer, Journal of clinical oncology, vol. 23, no 16, 2005, p. 3706-3712.
  • Miller K. et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer, The New England journal of medicine, vol. 357, no 26, 2007, p. 2666-2676.
  • Nugue G. Monitoring Monoclonal antibody delivery in oncology: the example of Bevacizumab. PLoS One. 2013, 8(8): e72021.
  • Parikh S.S. Advances in development of Bevacizumab, a humanized anti-angiogenic therapeutic monoclonal antibody targeting VEGF in cancer cells. Int. J. Pharm. Biomed. Sci 2012, 3(4), 155-163.
  • Perren T.J. A phase 3 trial of bevacizumab in ovarian cancer.  The New England journal of medicine, vol. 365, no 26, 2011, p. 2484-2496.
  • Sinapis C. Pharmacokinetics of intravitreal Bevacizumab (Avastin) in rabbits. Clinical Ophtalmology, 2011:5, 698-704.
  • Ternant D. An enzyme-Linked Immunosorbent Assay to study Bevacizumab Pharmacokinetics. The Drug Monit 2010; 32:647-652.
  • LISA-TRACKER Duo Bevacizumab
  • LISA-TRACKER anti-Bevacizumab
  • ImmunoTROL LISA-TRACKER Bevacizumab
  • ImmunoTROL LISA-TRACKER anti-Bevacizumab